medigraphic.com
ISSN 1025-0255 (Digital)

2015, Número 6

<< Anterior Siguiente >>

AMC 2015; 19 (6)


La linfoadenectomía mediastinal en la cirugía del cáncer pulmonar de células no pequeñas

García RME, Armas PBA, Koelig PR, Flagela CA

Idioma: Español
Referencias bibliográficas: 47
Paginas: 665-675
Archivo PDF: 476.27 Kb.


RESUMEN

Fundamento: la causa del cáncer del pulmón es multifactorial; existen riesgos genéticos, de exposición ambiental y de estilos de vidas. El tabaco se mantiene como el carcinógeno mejor conocido; sin embargo, a pesar del riesgo de la exposición a su humo, muchos fumadores de toda la vida no desarrollan un cáncer del pulmón.
Objetivos: realizar un recuento del estado del arte de la linfoadenectomía mediastinal en el tratamiento de la afectación ganglionar en el cáncer pulmonar.
Métodos: se realizó una búsqueda en las bases de datos Medline, Ebsco, Pubmed, Scielo y Redalycs; se utilizaron diferentes descriptores en idioma español e inglés.
Desarrollo: la linfoadenectomía en el estado clínico y patológico, así como la determinación de marcadores pronósticos de recurrencia y metástasis definen la supervivencia en pacientes con cáncer pulmonar.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spi-vack SD. Epidemiology of lung cancer: Diag-nosis and management of lung cancer, 3rd ed: American College of Chest Physicians evi-dence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S-29S.

  2. Cadelis G, Kaddah S, Bhakkan B, Quellery M, Deloumeaux J. [Epidemiology and incidence of primary lung cancer in a region with low to-bacco consumption: Guadeloupe (French West Indies). Data from the cancer registry 2008-2009]. Revue des maladies respiratoires. 2013;30(7):537-48.

  3. Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax. 2003 Sep;58(9):784-9.

  4. Shlomi D, Ben-Avi R, Balmor GR, Onn A, Peled N. Screening for lung cancer: time for large-scale screening by chest computed tomogra-phy. Eur Respir J. 2014 Jul;44(1):217-38

  5. Cerfolio RJ, Bryant AS, Minnich DJ. Complete thoracic mediastinal lymphadenectomy leads to a higher rate of pathologically proven N2 disease in patients with non-small cell lung cancer. The Annals of thoracic surgery. 2012;94(3):902-6.

  6. Deslauries J. Mediastinal lymph nodes: Ig-nore? Sample? Dissect? The role of mediasti-nal node dissection in the surgical manage-ment of primary lung cancer. Gen Thorac Car-diovasc Surg. 2012;60:724–34.

  7. Cahan WG, Watson WL, Pool JL. Radical pneu-monectomy. J Thorac Surg. 1951;22:449–473.

  8. Cahan WG. Radical lobectomy. J Thorac Cardi-ovasc Surg. 1960;39:555–572.

  9. D’Andrilli A, Venuta F, Rendina EA. the role of lymphadenectomy in lung cancer surgery. Thorac Surg Clin. 2012(22):227–237.

  10. Zheng H, Wang LM, Bao F, Jiang GN, Xie HK, Ding JA, et al. Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite. Lung Cancer. 2011(74):497–503.

  11. Kim AW. Lymph Node Drainage Patterns and Micrometastasis in Lung Cancer. Semin Thorac Cardiovasc Surg. 2009(21):298-308.

  12. Rouvie`re H. Les vaisseaux lymphatiques des poumons et les ganglions visce´raux intratho-raciques. Ann Anat Pathol. 1929;65:113–58.

  13. García Rodríguez ME. Estadificación y valora-ción mediastínica del cáncer del pulmón. Rev Cubana Cir [Internet]. 2010 Dic [citado 2013 Jun 03];49(4) Disponible en http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003474932010000400012&lng=es

  14. García Rodríguez ME, Armas Pérez BA, Armas Moredo K. Actualización en el tratamiento del cáncer pulmonar de células no pequeñas en etapa IIIA con afectación N2. Rev Cubana Cir [Internet]. 2012 Sep [citado 2013 Jun 03];51(3):[aprox. 16 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003474932012000300003&lng=es

  15. García Rodríguez ME, Armas Pérez BA, Armas Moredo K. Oligorrecurrencia a partir de un adenocarcinoma del pulmón. Utilidad de la resección. Arch Bronconeumol. 2014;50:46-7.

  16. Jawad H, Sirajuddin A, Chung JH. Review of the International Association for the Study of Lung Cancer Lymph Node Classification Sys-tem Localization of Lymph Node Stations on CT Imaging. Clin Chest Med. 2013(34):353–363.

  17. Borrie J. Primary carcinoma of the bronchus: prognosis following surgical resection. Ann R Coll Surg Engl. 1950;10:165–86.

  18. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive Medi-astinal Staging of Lung Cancer: ACCP Evi-dence-Based Clinical Practice Guidelines (2nd Edition). Chest. 2007;132;202-220.

  19. Detterbeck F, Puchalski J, Rubinowitz A, David Cheng D. Classification of the Thoroughness of Mediastinal Staging of Lung Cancer. CHEST. 2010;137(2):436–442.

  20. Terán MD, Brock MV. Staging lymph node me-tastases from lung cancer in the mediastinum. J Thorac Dis. 2014;6(3):230-236.

  21. Asamura H, Suzuki K, Watanabe S, Matsuno Y, Maeshima A, Tsuchiya RA. Clinicopathologi-cal study of resected subcentimeter lung can-cers: a favorable prognosis for ground glass opacity lesions. Ann Thorac Surg. 2003;76(4):1016–1022.

  22. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. Internation-al Association for the Study of Lung Cancer/American Thoracic Society/ European Respira-tory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Tho-rac Oncol. 2011;6(2):244–285.

  23. De Leyn P, Cooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;30:787-92.

  24. Gould MK, Wagner TH, Schultz EM, Xu X, Ghaus SJ, Provenzale D, et al. Facility-Level Analysis of PET Scanning for Staging Among US Veterans With Non-small Cell Lung Cancer. Chest. 2014;145(4):839-47.

  25. Huellner MW, Collen TD, Gut P, Winterhalder R, Pauli C, Diebold J, et al. Multiparametric PET/CT-perfusion does not add significant ad-ditional information for initial staging in lung cancer compared with standard PET/CT. EJNMMI research. 2014;4(1):6.

  26. Saettele TM, Ost DE. Multimodality systematic approach to mediastinal lymph node staging in non-small cell lung cancer. Respirology. 2014;19(6):800-8.

  27. Sánchez Sánchez R, Rodríguez Fernández A, Gómez Río M, Alkurdi Martínez A, Castellón Rubio VE, Ramos Font C, et al. Utilidad de la PET/TAC en la estadificación mediastínica del cáncer de pulmón de células no pequeñas en estadio III (N2). Rev Esp Med Nucl. 2011;30(4):211–216.

  28. Amini A, Lou F, Correa AM, Baldassarre R, Rimner A, Huang J, et al. Predictors for Lo-coregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal Down staging After Induction Chemotherapy and Surgery. Ann Surg Oncol. 2013;20:1934–1940.

  29. Rocco G, Peerone F, Rossi A, Gridelli C. Surgi-cal Management of Non-small Cell Lung Can-cer with Mediastinal Lymphadenopathy. Clini-cal Oncology. 2010;22:325–333.

  30. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.

  31. Libutti SK, Saltz LB, Rustgi AK, Tepper JE. Cancer de colon. In: Veincent De Vita Jr, Hell-man S, Rosenberg SA. Principles and Practice of Oncology. 7a ed. Philadelphia: Lippincot Wil-liam and Wilkins; 2005. p. 1061-1109.

  32. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB, et al. Impact of number of nodes retrieved on outcome in pa-tients with rectal cancer. J Clin Oncol. 2001;19:157–163.

  33. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in pa-tients with muscle invasive bladder cancer. J Urol. 2002;167:1295–1298.

  34. Polednak A. Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg. 2003;237:163–167.

  35. Weir L, Speers C, D’yachkova Y, Olivotto IA. Prognostic significance of the number of axil-lary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002;20:1793–1799.

  36. Krag D, Single R. Breast cancer survival ac-cording to number of nodes removed. Ann Surg Oncol. 2003;10:1152–1159.

  37. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gas-tric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–2077.

  38. Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, et al. Effectiveness of radi-cal systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg. 1998;227:138–44.

  39. Osarogiagbon RU, Yu X. Mediastinal lymh node examination and survival in resected early stage non-small cell lung cancer in the Surveil-lance, Epidemiology and End Results database. J Thorac Oncol. 2012;7:1798–1806.

  40. Ellis MC, Diggs BS, Vetto JT, Schipper PH. In-traoperative oncologic staging and outcomes for lung cancer resection vary by surgeon spe-cialty. The Annals of thoracic surgery. 2011;92(6):1958-63.

  41. Watanabe S, Asamura H. Lymph node dis-section for lung cancer: significance, strate-gy, and technique. J Thorac Oncol. 2009;4:652–7.

  42. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg. 2005;80:2051–6.

  43. von Meyenfeldt EM, Gooiker GA, van Gijn W, Post PN, van de Velde CJ, Tollenaar RA, et al. The relationship between volume or surgeon specialty and outcome in the surgical treat-ment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2012;7:1170-8.

  44. Ferraris VA, Saha SP, Davenport DL, Zwischen-berger JB. Thoracic surgery in the real world: does surgical specialty affect outcomes in pa-tients having general thoracic operations? Ann Thorac Surg. 2012;93:1041-7.

  45. Luft HS, Bunker JP, Enthoven AC. Should oper-ations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med. 1979;301:1364-9.

  46. Saínz Menéndez BA. El reto de la formación de nuestros cirujanos torácicos. Rev Cubana Cir [Internet]. 2013 Mar [citado 2015 Ene 19];52(1):[aprox. 1 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003474932013000100001&lng=es

  47. Tieu B, Schipper P. Specialty matters in the treatment of lung cancer. Seminars in thoracic and cardiovascular surgery. Semin Thorac Car-diovasc Surg. 2012 summer;24(2):99-105.




2020     |     www.medigraphic.com